Maureen Gottfried, DO
Neurology · Somers Point, NJNPI 1972652832
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $339 and has fallen 70.2% since, to $101 in 2025. That places this record below the midpoint for neurology clinicians in NJ, where the typical reported total is $1,560.
Across 59 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$172
- Harmony Biosciences LLC$95
- AstraZeneca$59
- Teva Pharmaceuticals USA, Inc.$47
- SK Life Science, Inc.$42
- Impel Pharmaceuticals Inc.$36
- plus $511 from 23 others
What the payments were for
- Food & beverage$88792%
- Education$758%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $172 |
| Harmony Biosciences LLC | 4 | $95 |
| AstraZeneca | 4 | $59 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| SK Life Science, Inc. | 3 | $42 |
| Impel Pharmaceuticals Inc. | 2 | $36 |
| UCB, Inc. | 2 | $34 |
| Johnson & Johnson | 2 | $33 |
| Argenx US, Inc. | 2 | $32 |
| Boston Scientific | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Lundbeck LLC | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Genentech USA, Inc. | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 2 | $27 |
| Lilly USA, LLC | 2 | $26 |
| EMD Serono, Inc. | 2 | $25 |
| Eisai Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| TG Therapeutics, Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Neurelis, Inc. | 1 | $15 |
| Sanofi | 1 | $14 |
| Aprecia Pharmaceuticals, LLC | 1 | $14 |
| W. L. Gore & Associates, Inc. | 1 | $13 |
| Biogen | 1 | $12 |
How this compares
$962 in reported general payments places this provider in the 40th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 39 | $438,587 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 25 | $205,390 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $186,209 |
| FingolimodFingolimod Hcl | 33 | $175,140 |
| Teriflunomide | 41 | $83,159 |
| GlatopaGlatiramer Acetate | 24 | $73,121 |
| NeuproRotigotine | 17 | $35,559 |
| Keppra XrLevetiracetam | 12 | $32,770 |
| RytaryCarbidopa/Levodopa | 12 | $32,359 |
| XcopriCenobamate | 14 | $32,001 |
| Nurtec OdtRimegepant Sulfate | 27 | $30,123 |
| UbrelvyUbrogepant | 20 | $20,216 |
| Memantine Hcl | 457 | $19,071 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 44 | $17,292 |
| Dimethyl Fumarate | 32 | $13,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Neupro | $34 | $35,55917 claims |
| SK Life Science, Inc.Xcopri | $42 | $32,00114 claims |
| AbbVieUbrelvy | $172 | $20,21620 claims |
| Upsher-smith Laboratories LLCTopiramate | $16 | $2,666158 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 521 neurology providers in New Jersey.
Other neurology in Somers Point
- Joshua DanielSomers Point$42K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
- Mario VukicHackensack$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.